J Korean Ophthalmol Soc.  2013 Sep;54(9):1423-1428.

Effects of Prednisolone and Loteprednol Eyedrops on the Proliferation of Human Tenon's Capsule Fibroblasts

• Kang SH
• Kim JW

Abstract

PURPOSE
To compare the effect of loteprednol etabonate (LE) with prednisolone acetate (PDA) drops on the proliferation of human Tenon's capsule fibroblasts (HTFBs).
METHODS
Primarily cultured HTFBs were treated with serially diluted PDA and LE for 3 days. Cellular survival was determined by a rapid colorimetric assay using MTT. RT-PCR was performed to determine the relative expression of TGF-beta mRNA in response to LE and PDA.
RESULTS
PDA inhibited proliferation of HTCF in a dose-dependent manner and LE inhibited significantly the proliferation of HTCF at the higher concentration of 50 microg/ml (p < 0.05). Compared to LE, PDA inhibited proliferation of HTCF significantly at each diluted concentration (p < 0.05). Expressions of TGF-beta were decreased as the concentration of both PDA and LE increased. PDA decreased expression of TGF-beta more significantly compared to LE at each concentration (p < 0.05).
CONCLUSIONS
Although LE has offered promising anti-inflammatory efficacy with decreased impact on intraocular pressure, LE may be less effective than PDA in inhibiting fibroblast proliferation and may be not comparable to PDA in preventing excessive scarring after glaucoma filtering surgery.

Keyword

Fibroblasts; Loteprednol etabonate; Prednisolone acetate; Proliferation; TGF-beta

MeSH Terms

Androstadienes
Cicatrix
Fibroblasts
Filtering Surgery
Glaucoma
Humans
Intraocular Pressure
Ophthalmic Solutions
Prednisolone
RNA, Messenger
Tenon Capsule
Transforming Growth Factor beta
Loteprednol Etabonate
Androstadienes
Ophthalmic Solutions
Prednisolone
RNA, Messenger
Transforming Growth Factor beta

Figure

• 

  Figure 1. Effect of 1% prednisolone acetate on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Prednisolone acetate inhibited significantly the proliferation of fibroblasts compared to non-exposed controls at each concentration: * p < 0.05.

• 

  Figure 2. Effect of 0.5% loteprednol etabonate on the pro-liferation of human Tenon's capsule fibroblasts in tissue culture. Loteprednol etabonate inhibited significantly the pro-liferation of fibroblasts only at concentration of 50 μ g/ml com-pared to non-exposed controls: * p < 0.05.

• 

  Figure 3. Comparison of the effects of topical steroids on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Prednisolone acetate (PDA) inhibited significantly the proliferation of fibroblasts more compared to loteprednol eta-bonate (LE) at each concentration: * p < 0.05.

• 

  Figure 4. Effect of topical steroids on the expression of TGF-β mRNA in human Tenon's capsule fibroblasts. Prednisolone acetate (PDA) inhibited more significantly the expression of TGF-β mRNA compared to loteprednol etabonate (LE) at each concentration: * p < 0.05.

Reference

References

1. Khaw PT, Occleston NL, Schultz G. . Activation and sup-pression of fibroblast function. Eye (Lond). 1994; 8((Pt 2)):188–95.

2. Skuta GL, Parrish RK 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987; 32:149–70.

3. Grierson I, Joseph J, Miller M, Day JE. Wound repair: The fibro-blast and the inhibitor of scar formation. Eye (Lond). 1988; 2((Pt 2)):135–48.

4. Tahery MM, Lee DA. Review: pharmacologic control of wound healing in glaucoma filtration surgery. J Ocul Pharmacol. 1989; 5:155–79.

5. Chen CW, Huang HT, Bair JS, Lee CC. Trabeculectomy with si-multaneous topical application of mitomycin-C in refractory glaucoma. J Ocul Pharmacol. 1990; 6:175–82.

6. Khaw PT, Sherwood MB, Doyle JW. . Intraoperative and post operative treatment with 5-fluorouracil and mitomycin-c: long term effects in vivo on subconjunctival and scleral fibroblasts. Int Ophthalmol. 1992; 16((4-5)):381–5.

7. Sugar HS. Clinical effect of corticosteroids on conjunctival filtering blebs; a case report. Am J Ophthalmol. 1965; 59:854–60.

8. Starita RJ, Fellman RL, Spaeth GL. . Short- and long-term effects of postoperative corticosteroids on trabeculectomy. Ophthalmology. 1985; 92:938–46.

9. Nguyen KD, Lee DA. Effect of steroids and nonsteroidal antiin-flammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci. 1992; 33:2693–701.

10. Araujo SV, Spaeth GL, Roth SM, Starita RJ. A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy. Ophthalmology. 1995; 102:1753–9.

11. Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012; 47:66–80.

12. Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation. BioDrugs. 1998; 10:329–39.

13. Pavesio CE, Decory HH. Treatment of ocular inflammatory con-ditions with loteprednol etabonate. Br J Ophthalmol. 2008; 92:455–9.

14. Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012; 32:507–17.

15. Bodor N, Bodor N, Wu WM. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res. 1992; 11:525–30.

16. Rajpal RK, Digby D. . Intraocular pressure ele-vations with loteprednol etabonate: a retrospective chart review. J Ocul Pharmacol Ther. 2011; 27:305–8.

17. Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus pre-dnisolone acetate 1.0% for the treatment of inflammation after cat-aract surgery. J Cataract Refract Surg. 2013; 39:168–73.

18. Loteprednol Etabonate US Uveitis Study Group. Controlled evalu-ation of loteprednol etabonate and prednisolone acetate in the treat-ment of acute anterior uveitis. Am J Ophthalmol. 1999; 127:537–44.

19. Moses HL, Tucker RF, Leof EB. . Type beta transforming growth factor is a growth stimulator and a growth inhibitor. Cancer Cells. 1985; 3:65–71.

20. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci. 2000; 41:756–63.

21. Connor TB Jr, Roberts AB, Sporn MB. . Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989; 83:1661–6.

22. Roberts AB, Sporn MB, Assoian RK. . Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986; 83:4167–71.

23. Cordeiro MF. Beyond Mitomycin: TGF-beta and wound healing. Prog Retin Eye Res. 2002; 21:75–89.

24. Jampel HD. Ascorbic acid is cytotoxic to dividing human Tenon's capsule fibroblasts. A possible contributing factor in glaucoma fil-tration surgery success. Arch Ophthalmol. 1990; 108:1323–5.

25. Mosmann T. Rapid colorimetric assay for cellular growth and sur-vival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65((1-2)):55–63.

26. Clark AF. Basic sciences in clinical glaucoma: steroids, ocular hy-pertension, and glaucoma. J Glaucoma. 1995; 4:354–69.

27. Cantrill HL, Palmberg PF, Zink HA. . Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975; 79:1012–7.

28. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glau-comatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994; 59:723–7.

29. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990; 9:963–9.

30. Kay EP, Lee HK, Park KS, Lee SC. Indirect mitogenic effect of transforming growth factor-beta on cell proliferation of subcon-junctival fibroblasts. Invest Ophthalmol Vis Sci. 1998; 39:481–6.

31. Wilensky JT, Snyder D, Gieser D. Steroid-induced ocular hyper-tension in patients with filtering blebs. Ophthalmology. 1980; 87:240–4.

32. Van Buskirk EM. Cysts of Tenon's capsule following filtration surgery. Am J Ophthalmol. 1982; 94:522–7.